CAMBRIDGE, Mass. & DUBAI, United Arab Emirates--(BUSINESS WIRE)--GenePeeks, Inc., a computational genomics company focused on transforming genetic disease risk analysis, and Alliance Global Group (AGBL) today announced a new partnership to bring GenePeeks’ Virtual Progeny Analytics (VPA) technology platform to select markets in the Middle East and Africa. AGBL is the largest biomedical gateway in these markets.
This collaboration marks another international market for the GenePeeks Preconception Screen, which identifies combined parental risk of passing on more than 1,000 serious genetic diseases. Under the terms of the agreement, AGBL will expand its genetic testing by offering GenePeeks Preconception Screen to patients, healthcare providers and laboratories in the Middle East and Africa. AGBL will also introduce additional applications of GenePeeks’ technology through partnerships with centers of excellence throughout the region.
“We are honored to partner with Alliance Global to address the significant unmet need in these markets for comprehensive preconception screening,” said Anne Morriss, Co-Founder and Chief Executive Officer of GenePeeks. “AGBL’s regional breadth and market knowledge, combined with the analytic power of our advanced computational platform, will give more prospective parents the information and support they need to protect their future families. AGBL is another strong partner for our growing presence outside of the U.S.”
Dr. Tamer Degheidy, Group CEO at Alliance Global stated, “GenePeeks Preconception Screen is an important addition to our growing portfolio of genetic tests, and we’re excited to offer this comprehensive, state-of-the art approach, which reduces the population biases that are associated with traditional carrier screening. It is the first step in our shared mission to transform gene-based clinical applications using GenePeeks’ core technology platform.”
About GenePeeks’ Technology
GenePeeks’ comprehensive
approach, called Virtual Progeny Analytics (VPA), uniquely integrates
simulated DNA information from two genetic participants to predict the
future genome of a child prior to conception. For every mutation in
these hypothetical genomes, the company computes a proprietary Variant
Gene Dysfunction (VGD) score that predicts gene function and associated
disease risk. This next generation approach allows GenePeeks to cover an
expanded number of diseases with increased sensitivity and evaluate
variants that may remain uncharacterized by other genetic tests, while
avoiding the confusion and anxiety that can be associated with carrier
testing. In contrast to carrier screening, which identifies parental
carrier status, GenePeeks focuses on a future child’s true risk of
disease inheritance. GenePeeks offers this physician-ordered service
through its CLIA certified clinical laboratory.
About GenePeeks
GenePeeks is a computational genomics
company focused on identifying inherited disease risk in future
generations. GenePeeks’ patented technology digitally combines the
genetic information of two potential parents, simulating the complex
genetic interactions that occur naturally in human reproduction. The
company’s proprietary platform creates and analyzes thousands of Virtual
Progeny to uncover disease risk that cannot be seen with alternative
screening tools. GenePeeks offers this physician-ordered service through
its CLIA certified clinical laboratory. GenePeeks is privately held,
with corporate offices in Cambridge, Mass. For more information, visit www.genepeeks.com
GenePeeks’ next-generation screening technology is available today. For more information about becoming a partner, please contact support@genepeeks.com
About Alliance Global Group (AGBL)
The AGBL Group of
companies is the largest biomedical gateway to the emerging markets of
the Middle East, Africa and Asia. The group is dedicated to bringing
innovative technologies and products to researchers, clinicians, and
diagnostic users in the emerging healthcare markets within the MENA
region. The group employs dedicated teams of product and applications
specialists, and has many offices across the region offering
distribution, consulting and product development services to
world-renowned manufacturers of biomedical technologies. The group’s
stated mission is to improve the lives of the region’s inhabitants
through novel biomedical technologies and products. For more
information, please visit: www.agbl.net
